The medication is generally used in situations involving certain distressing symptoms related to specific mood and anxiety disorders. It is commonly utilized in conditions characterized by periods of heightened symptoms that interfere with daily functioning, such as Major Depressive Disorder (MDD) and presentations involving Panic Disorder.

Therapeutic Focus and Relief

The medicine is commonly used to provide symptomatic relief for MDD. It is relevant for easing symptom clusters that may become intense or disruptive, including pervasive feelings of sadness and the significant loss of interest or pleasure. The treatment may assist with lifting depressed mood and supports general well-being during symptomatic phases. It is applied when symptoms become temporarily overwhelming, and the support contributes to easing the overall symptom load, which may help patients cope more steadily with symptom fluctuations. The support helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Focus on Mood and Functional Symptoms
Primary Domain	Major Depressive Disorder (MDD)
Symptom Targets	Emotional distress, fatigue, sleep disruption, panic attacks
General Benefit	Supports maintenance of functional stability and emotional balance

“The medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”

This information is derived from official regulatory documents and defines which populations are eligible to use the medicine based on safety considerations.

Absolute Contraindications

The medicine must not be used by individuals who are currently taking or have recently stopped (within 14 days) Monoamine Oxidase Inhibitors (MAOIs), or who are taking Pimozide. Use is also prohibited in patients with known hypersensitivity to Citalopram and, per some international labels, in those with a known QT-interval prolongation or congenital long QT syndrome.

Eligibility by Population and Condition

Population/Condition	Regulatory Rule
Pediatric Patients (<18 years)	Not approved for use; should not be used in children and adolescents [1.4, 2.3].
Older Adults (ge 60 years)	The maximum recommended dose is restricted to 20 mg daily [1.1, 1.4].
Hepatic Impairment	The maximum recommended dose is restricted to 20 mg daily [1.1, 1.4].
Pre-existing Cardiac Risk	Use is not recommended or avoided in patients with conditions like bradycardia or uncompensated heart failure [1.4, 1.5].
Pregnancy/Lactation	Caution is advised; generally not recommended during pregnancy unless benefits outweigh risks, and monitoring is needed during lactation [1.1, 1.2].

Official regulatory bodies classify the adult population as eligible for use, but they impose strict restrictions based on age, reduced organ function, and cardiovascular status to mitigate potential risks associated with Citalopram.

The regulatory profile for Citalopram interactions is defined by high-level pharmacokinetic and pharmacodynamic constraints. Co-administration with certain substances is strictly prohibited due to severe adverse outcomes documented in official labeling.

The combination with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is absolutely contraindicated because of the significant risk of Serotonin Syndrome. A mandatory 14-day washout period must elapse when switching between Citalopram and an MAOI. The combination with Pimozide is also forbidden, as documented studies show Citalopram increases the plasma concentration of Pimozide, raising the risk of QT interval prolongation.

Pharmacodynamic interactions extend to other serotonergic agents (like Triptans and Lithium), increasing the additive risk of Serotonin Syndrome. Co-administration with antiplatelet drugs or anticoagulants, such as NSAIDs and Warfarin, results in a documented increase in the risk of bleeding abnormalities.

From a pharmacokinetic perspective, inhibitors of the CYP2C19 enzyme (such as Omeprazole) decrease Citalopram clearance, leading to increased drug exposure. This PK effect necessitates a formal regulatory restriction on the maximum daily dose for patients taking these inhibitors. This restriction also applies to documented CYP2C19 Poor Metabolizers and those with hepatic impairment, as their reduced clearance increases Citalopram exposure. Furthermore, the use of herbal supplements like St. John's Wort is not recommended due to its serotonergic potential. Food does not affect Citalopram absorption.

Blocking Pro-inflammatory IL-17 Signaling

This mechanism involves Опра specifically targeting the IL-17 Receptor A (IL-17RA) subunit, preventing pro-inflammatory cytokines IL-17A and IL-17F from docking and activating their respective pathways. This interaction suppresses the T H17-driven immune response, which involves a reduction of excessive mediator activity and the potential for chronic tissue inflammation and cellular hyperproliferation.

---

Modulating Downstream Cellular Responses

Опра engages mechanisms that regulate the immediate downstream effects of IL-17 signaling, specifically inhibiting the sequences that lead to the production of chemokines and tissue-degrading enzymes. By modifying these early molecular steps, the drug influences the regulation of targeted pathways, affecting physiological responses and IL-17-driven catabolic activity in tissues like bone and cartilage.

Official Administration Guidelines

The administration of Опра (Citalopram) is based on established protocols regarding its use. The medication is delivered exclusively via the oral route, primarily available in tablet strengths of 10 mg, 20 mg, and 40 mg, as well as an oral solution.

The dosing regimen is based on a once-daily schedule, which can be taken either in the morning or the evening, and administration is permissible with or without food. For adults under 60 years of age, the standard initiation dosage is 20 mg once daily. If a dose adjustment is necessary, any increase toward the maximum recommended dose of 40 mg once daily generally does not occur until an interval of at least one week has passed.

Usage is also defined by population-specific restrictions. The maximum recommended daily dose is restricted to 20 mg for certain patient groups, including individuals who are 60 years of age or older and patients who have hepatic impairment. For the oral solution form, the liquid must be mixed with water or other appropriate fluid prior to consumption.

The duration of treatment often extends into a maintenance phase, requiring continued use for at least six months following initial response. When treatment is to be concluded, abrupt cessation is typically avoided. The medicine's dose is gradually reduced over a period, such as one to two weeks, to manage the procedural steps of discontinuation.

Research Evidence / Overview of Studies for Опра (Citalopram)

This overview summarizes the available research evidence for Citalopram, drawing only from official regulatory and peer-reviewed scientific sources. It describes what types of studies were conducted, what they focused on, and what areas of research are still uncertain.

---

Evidence for Use in Major Depressive Disorder (MDD)

The research base for Citalopram, in the context of Major Depressive Disorder (MDD), primarily consists of short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time by monitoring changes in symptom intensity or variability over periods often lasting 8 to 12 weeks. The studies mainly included adult outpatients presenting with symptoms associated with acute or disruptive episodes of MDD.

Research focused on two primary outcomes: measures of response (a significant symptom reduction) and remission (a return to a nearly symptom-free state). Findings describe patterns observed in the studies where the difference in measured symptoms between Citalopram and placebo recipients was recorded in the short term. The evidence base for achieving full remission has been described as less consistent than the data for symptom reduction.

---

Evidence for Use in Panic Disorder (PD)

Research examining Citalopram for Panic Disorder (PD) involves various placebo-controlled RCTs and systematic reviews. These trials were applied in research contexts involving fluctuating or unstable symptoms of panic, generally enrolling adult patients with the condition. The main study outcomes examined were related to episodic or acute changes, specifically monitoring the frequency of panic attacks.

Studies conducted during periods of increased symptom activity reported that the observed populations experienced a greater recorded reduction in the number of panic attacks compared to the placebo group. The evidence quality and certainty for Citalopram in the context of Panic Disorder has been described as moderate.

---

Quality of Evidence and Areas of Uncertainty

The evidence base for Citalopram in MDD includes a large number of placebo-controlled trials. However, some limitations noted by regulatory bodies and systematic reviews include that evidence quality varies across studies, particularly older ones where sample sizes were modest. The most significant research gaps include a relative lack of data characterizing long-term effects beyond one year. Research provides insight into group patterns, not personal outcomes, and continued research is needed to refine the understanding of the medicine’s effects in specific patient subgroups.

Common questions about Опра (FAQ)

---

Q: Can Опра be used long-term?

Studies and official information indicate that the research evidence for this medicine has focused primarily on short-term efficacy trials, typically lasting 8 to 12 weeks. Regulatory bodies have noted a relative lack of data characterizing the long-term effects of the medicine for use beyond one year.

Q: How does Опра affect sleep?

Official labeling documents state that the medicine can affect sleep patterns. Both insomnia (difficulty falling or staying asleep) and somnolence (feeling drowsy or very sleepy) are reported as very common adverse reactions.

Q: Can I take Опра if I'm already taking a common over-the-counter pain reliever?

Regulatory documents caution that using this medicine alongside antiplatelet drugs or anticoagulants is associated with an increased risk of bleeding abnormalities. This includes certain common pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs). The official prescribing information provides detailed guidance on drug interactions.

Q: Can I take vitamins or supplements while on Опра?

Regulatory guidance specifically recommends against the use of certain herbal supplements, such as St. John's Wort, due to its potential to increase the serotonergic activity of the medicine. Official documents do not provide general guidance for all vitamins and supplements.

Q: What happens when you stop taking Опра?

Regulatory documents state that adverse reactions may occur when the medicine is stopped. For this reason, official guidance describes a gradual dose reduction over a period as the procedure for discontinuation, rather than stopping abruptly.

Q: Does Опра affect laboratory test results?

The medicine’s regulatory profile notes that its effects are processed in the body by the CYP2C19 enzyme. This is a factor that may be relevant to certain diagnostic or genetic tests used to evaluate liver function or how the body processes drugs.

Q: Is Опра the same as [similar drug name]?

The official product documentation classifies the medicine, which contains Citalopram, as chemically and pharmacologically related to other Selective Serotonin Reuptake Inhibitors (SSRIs). It is further noted that Citalopram is chemically defined as a racemic mixture, which is a distinction from related single-enantiomer counterparts.

Q: How quickly does Опра typically start working?

According to authoritative sources, antidepressant effects may take one to four weeks to occur in the patient population. Official information notes that it may take a month or longer before an individual begins to feel therapeutic benefits.

Q: What is the expected duration of effect after taking Опра?

Pharmacokinetic data published in regulatory documents indicates that the medicine has a mean terminal half-life of approximately 35 hours in the body.

Q: What is the difference between Опра and other treatments for [condition]? (High-level question)

The medicine is officially classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification is based on its specific mechanism of action, which differentiates it from older treatments for mood disorders, such as tricyclic antidepressants.

Q: Is Опра a controlled substance?

U.S. regulatory documents from the DEA and other bodies classify the medicine (Citalopram) as having no controlled substance schedule.

Q: Is Опра considered a 'new' medicine?

The medicine containing Citalopram is not considered new. Official records show it was initially approved by the U.S. Food and Drug Administration (FDA) in 1998.

Q: Is it true that Опра is only available by prescription?

Official regulatory labeling classifies the medicine as a Human Prescription Drug and it is not available over-the-counter.

Q: What distinguishes Опра from older treatments for the same condition?

The medicine is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This modern pharmacological class is characterized by a specific mechanism of action that differentiates it from older antidepressant agents, which affect a broader range of neurochemical systems.

Q: What is the official purpose of the inactive ingredients in Опра?

Official labeling lists the specific inactive ingredients that are included in the product composition. These ingredients are necessary to provide features such as coloring, binding agents, or stabilization of the tablet or oral solution.

Q: Is Опра considered a high-risk medication by regulatory bodies?

Regulatory documents contain a Boxed Warning that highlights the risk of suicidal thoughts and behaviors in young adults. This is a formal high-level safety constraint noted at the initiation of therapy or following dose changes.

Q: Is there specific advice about sun exposure while using Опра?

Official patient information for drugs in this class (SSRIs) sometimes notes the potential for photosensitivity. Because of this, some official information indicates caution regarding sun exposure, as the medicine may increase the skin's sensitivity to sunlight.

Q: Is it normal to feel [non-serious sensation] after starting Опра?

The label classifies common adverse reactions like nausea, dry mouth, and headache in its frequency sections. The documentation of these effects by regulatory bodies indicates they are widely reported and often reported during initial treatment.

Q: What is the eligibility for taking Опра based on general health conditions?

Official eligibility rules primarily focus on specific high-risk factors for exclusion. These include advanced age (over 60), reduced liver function, pre-existing cardiac risk factors, and the use of certain other medications (like MAOIs).

Q: Are there known issues with driving or operating machinery while on Опра?

Regulatory warnings for drugs that affect the central nervous system caution that side effects such as drowsiness (somnolence) and dizziness may affect a person's ability to drive or safely operate machinery.

Q: Does Опра cause weight gain or loss?

Official labeling documents list both decreased weight and increased weight as common adverse reactions. These effects were observed in 1% to 10% of patients in clinical settings.

Q: Do studies support the use of Опра for all registered indications?

Research evidence has been published for its use in Major Depressive Disorder and Panic Disorder. However, systematic reviews of the evidence base note that the quality of evidence varies across some of the studies.

Q: Does Опра interact with certain foods or drinks?

Official documents state that the presence of food does not affect the absorption of the medicine. However, the combination of this medicine with alcohol is cautioned against by authoritative sources.

The official storage and disposal guidelines for Citalopram (Опра) are set by regulatory authorities to ensure product stability and environmental safety.

---

Storage Conditions

Citalopram tablets and oral solution must be stored at controlled room temperature. The product requires protection from both light and moisture. All forms of the medicine must be stored out of the reach of children to prevent accidental ingestion.

Stability and Container Rules

The oral solution requires the bottle to be kept tightly closed and must be discarded 60 days after the bottle is first opened.

Disposal Instructions

Unused or expired Citalopram should not be disposed of in wastewater (sinks or toilets). The product must be returned to a pharmacist or a local drug take-back collection point according to official local pharmaceutical waste requirements.